Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for Lucid Diagnostics (LUCD) over the last 4 years, with Q3 2025 value amounting to $9.9 million.

  • Lucid Diagnostics' Gains from Investment Securities rose 1460.15% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year increase of 1460.15%. This contributed to the annual value of $8.6 million for FY2024, which is 5708.86% up from last year.
  • Latest data reveals that Lucid Diagnostics reported Gains from Investment Securities of $9.9 million as of Q3 2025, which was up 1460.15% from $9.8 million recorded in Q2 2025.
  • Lucid Diagnostics' Gains from Investment Securities' 5-year high stood at $10.0 million during Q1 2025, with a 5-year trough of $2.6 million in Q4 2022.
  • Over the past 4 years, Lucid Diagnostics' median Gains from Investment Securities value was $8.7 million (recorded in 2024), while the average stood at $7.7 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 11456.43% in 2023, then soared by 1243.51% in 2025.
  • Quarter analysis of 4 years shows Lucid Diagnostics' Gains from Investment Securities stood at $2.6 million in 2022, then skyrocketed by 114.56% to $5.5 million in 2023, then soared by 57.09% to $8.6 million in 2024, then grew by 14.81% to $9.9 million in 2025.
  • Its Gains from Investment Securities was $9.9 million in Q3 2025, compared to $9.8 million in Q2 2025 and $10.0 million in Q1 2025.